Michael King
Stock Analyst at EF Hutton
(0.79)
# 3,937
Out of 4,983 analysts
116
Total ratings
34.43%
Success rate
-15.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $12.18 | +5,236.62% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $6.48 | +18,097.53% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $4.10 | +168.29% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $2.02 | +1,484.16% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $2.43 | +2,718.93% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $12.50 | +1,500.00% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.45 | +472.41% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $575.06 | +49.90% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $39.14 | -38.68% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $4.48 | +3,605.36% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $8.62 | +387.24% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $461.24 | -34.09% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $12.27 | +845.40% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.61 | +185.32% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $32.34 | -25.79% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $5.69 | +210,796.31% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $19.39 | +137.24% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $36.60 | +162.30% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.77 | +4,601.58% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $12.54 | +147.21% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $752.32 | -95.21% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $12.18
Upside: +5,236.62%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $6.48
Upside: +18,097.53%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $4.10
Upside: +168.29%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $2.02
Upside: +1,484.16%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $2.43
Upside: +2,718.93%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $12.50
Upside: +1,500.00%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.45
Upside: +472.41%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $575.06
Upside: +49.90%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $39.14
Upside: -38.68%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.48
Upside: +3,605.36%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $8.62
Upside: +387.24%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $461.24
Upside: -34.09%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $12.27
Upside: +845.40%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $3.61
Upside: +185.32%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $32.34
Upside: -25.79%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $5.69
Upside: +210,796.31%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $19.39
Upside: +137.24%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $36.60
Upside: +162.30%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.77
Upside: +4,601.58%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $12.54
Upside: +147.21%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $752.32
Upside: -95.21%